Zepbound for Teens: Is It Approved? New Trial Results

The short answer

Zepbound for teens is not FDA approved. As of November 15, 2026, the Zepbound label covers adults only and says safety and effectiveness have not been established in pediatric patients. On November 14, 2026, Eli Lilly said that in its phase 3 SURMOUNT-ADOLESCENTS trial, Zepbound lowered BMI by an average of 21.4% at 72 weeks in teens aged 12 to under 18 with obesity, and more than half no longer met the BMI criteria for obesity. Full results and safety data are not public yet. Parents who take a GLP-1 themselves can use Sharpy to keep their own protein and workouts on track.

Is Zepbound approved for teens, and is it safe for them? No, Zepbound for teens is not FDA approved. As of November 15, 2026, the label covers adults only. But there is fresh news. On November 14, 2026, Eli Lilly shared the first results from its phase 3 teen trial, SURMOUNT-ADOLESCENTS. Zepbound lowered BMI by an average of 21.4% at 72 weeks in teens aged 12 to under 18 with obesity. More than half of them no longer met the BMI criteria for obesity. The full results, including side effects, are not public yet.

This guide explains what is known, what is still missing, and which options are approved for teens today. It is information for families, not medical advice. Any decision about a teen and a weight-loss medicine belongs with a pediatric doctor.

Is Zepbound approved for teens?

No. Zepbound (tirzepatide) is made by Eli Lilly. The FDA approves it for two uses, both in adults: long-term weight management, and moderate to severe obstructive sleep apnea in adults with obesity.

Section 8.4 of the current label says it in one line: the safety and effectiveness of Zepbound have not been established in pediatric patients. Lilly's November 14 release repeats that it is not known if Zepbound is safe and effective for use in children.

Here is where the tirzepatide brands and the approved teen options stand, per the current FDA labels:

Drug Approved under 18? Youngest age Approved use in that age group
Zepbound (tirzepatide) No Adults only None yet
Mounjaro (tirzepatide) Yes 10 Type 2 diabetes only
Wegovy injection (semaglutide) Yes 12 Obesity
Saxenda (liraglutide) Yes 12 Obesity

Mounjaro and Zepbound are the same drug. Only Mounjaro has a pediatric approval, and only for blood sugar control in type 2 diabetes. Our Zepbound vs Mounjaro guide explains why one drug has two names.

What did the Zepbound teen trial show?

Lilly put out the first numbers in a press release tied to ObesityWeek 2026, a medical meeting held November 14 to 17 in Washington, D.C. The teen data is set for an oral session on Sunday, November 15.

What Lilly reported:

  • BMI: Zepbound lowered BMI by an average of 21.4% at 72 weeks in teens aged 12 to under 18 with obesity.
  • Obesity status: more than half no longer met the BMI criteria for obesity at 72 weeks.
  • Quality of life: teens reported better weight-related quality of life, including physical comfort and body esteem.

What the trial looked like, per its ClinicalTrials.gov record (NCT06075667):

Trial detail SURMOUNT-ADOLESCENTS
Phase 3, randomized, double-blind, placebo-controlled
Who 160 teens aged 12 to 17
Entry rule BMI at or above the 95th percentile, or 85th to 95th with a weight-related condition
Treatment Tirzepatide or placebo shot once a week
Main measure Percent change in BMI from the start to week 72
Status Main results in; long-term follow-up continues

Doctors use BMI change, not pounds, for teens. Teens are still growing taller, so body weight alone can mislead.

What is still not known?

A lot. Reuters noted that Lilly has not yet released the full results. The press release leaves out these points:

  • The placebo result. We do not know how the placebo group did, so we cannot say how much of the 21.4% came from the drug.
  • The doses. The release does not say which doses teens took.
  • Side effects. No rates for nausea, vomiting or anything else were given.
  • Growth and puberty. Nothing has been shared on height, bone or puberty.
  • A journal paper. No peer-reviewed publication was named.
  • An FDA filing. Lilly did not say when it will ask the FDA to add teens to the label.

We will update this guide when the full data is presented or published.

Is Zepbound safe for teens?

It is too early to say. Safety in teens is exactly what the full trial data must show, and that data is not out.

There is one related clue. The Mounjaro label describes a trial of tirzepatide in 99 children and teens with type 2 diabetes. It says side effects were similar to adults, except for more vomiting, belly pain and low blood sugar. Those were kids with diabetes on diabetes doses, so it may not carry over to teens with obesity.

Zepbound also carries a boxed warning about thyroid C-cell tumors seen in rats. That warning applies at every age. Our thyroid warning guide explains what it means.

How does Zepbound compare to Wegovy for teens?

No trial has tested the two drugs against each other in teens. The table puts the topline next to the Wegovy teen trial from the Wegovy label. Treat it as a rough side-by-side, not a contest. The trials had different teens, lengths and rules.

Zepbound (SURMOUNT-ADOLESCENTS) Wegovy (teen trial on the label)
Teens in trial 160 201
Length 72 weeks 68 weeks
Average BMI change on drug -21.4% -16.1%
Average BMI change on placebo Not released +0.6%
Source Lilly press release FDA label
Approved for teens No Yes, from age 12

For the adult head-to-head data, see semaglutide vs tirzepatide.

Can teens take Zepbound now?

Not on label. The approved GLP-1 choices for a teen with obesity are Wegovy injection and Saxenda, both from age 12. The American Academy of Pediatrics said in its 2023 guideline that doctors should offer weight-loss medicine to teens 12 and older with obesity, on top of nutrition, activity and family support. Our GLP-1 for teens guide covers each approved drug, and GLP-1 for kids under 12 covers younger children.

Do not buy compounded or "research" tirzepatide for a teen. Those products are not FDA approved, and no one has checked their dose or purity.

If your teen is already on a prescribed GLP-1, the basics matter even more than for adults. A growing body needs enough protein, calcium, iron and energy, and a pediatric dietitian should set those numbers. Strength work or sports a few times a week helps keep muscle. Regular checkups track height and puberty.

Many parents reading this take Zepbound themselves. Teens copy what they see at home. Sharpy is built for adults on a GLP-1: one protein target, one 20-minute workout and one Shape Score a day. Keeping your own muscle while the scale drops is the habit you want your teen to see.

When will Zepbound be approved for teens?

No one knows yet. Three things have to happen first: Lilly shares the full data, Lilly files with the FDA, and the FDA reviews it. Lilly has not given a date for any of them.

A second trial is also running. SURMOUNT-ADOLESCENTS-2 (NCT06439277) plans to enroll about 300 teens with obesity and at least two weight-related conditions. It is still recruiting, and its main results are expected around October 2027.

The bottom line

Zepbound for teens is not approved, and its safety in teens has not been shown in public data. The first trial result is strong: BMI down 21.4% on average at 72 weeks. But the placebo number, the doses and the side effects are still missing. Until the FDA acts, Wegovy injection and Saxenda are the approved options from age 12, and a pediatric doctor should guide the choice. For the adults in the house, Sharpy keeps protein, a short workout and progress in one daily check-in.

Sources

Questions people ask

Is Zepbound approved for teens?

No. As of November 15, 2026, Zepbound is FDA approved for adults only. The label says safety and effectiveness have not been established in pediatric patients. Lilly reported first teen trial results on November 14, 2026, but it has not announced an FDA filing for teens.

Is Zepbound safe for teens?

That is not known yet. Lilly has shared how much BMI dropped in its teen trial, but it has not released the safety results. Lilly's own safety summary says it is not known if Zepbound is safe and effective for use in children. The full data will show side effect rates and any effects on growth.

Can teens take Zepbound?

Not on label. A doctor would be prescribing it outside its approved use, and insurers usually do not pay for that. For teens 12 and older with obesity, the FDA-approved GLP-1 options today are Wegovy injection and Saxenda. A pediatric doctor decides what fits.

What is the age limit for Zepbound?

The Zepbound label is for adults, which means 18 and older. The same drug, tirzepatide, is approved under the brand Mounjaro for type 2 diabetes in children 10 and older, but Mounjaro is not approved for weight loss at any age.

What did the Zepbound teen trial show?

Lilly said Zepbound lowered BMI by an average of 21.4% at 72 weeks in teens aged 12 to under 18 with obesity. More than half no longer met the BMI criteria for obesity. Teens also reported better weight-related quality of life. The placebo result, doses and side effects have not been released.

When will Zepbound be approved for teens?

There is no date. Lilly has not said when it will ask the FDA to add teens to the Zepbound label. A second teen trial, SURMOUNT-ADOLESCENTS-2, is still recruiting and its main results are expected around October 2027, according to ClinicalTrials.gov.

Is Mounjaro approved for kids?

Yes, but only for type 2 diabetes. The Mounjaro label covers children and teens 10 and older with type 2 diabetes. It is not approved for weight management. Zepbound is the tirzepatide brand for weight loss, and it is adult-only for now.

Read next